Lam Research Corp. diskutieren
Lam Research Corp.
WKN: 869686 / Symbol: LRCX / Name: Lam Research / Aktie / Halbleiter / Large Cap /
7.371,0 €
3,99 %
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Cantor Fitzgerald from $115.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its "underweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $92.00 price target on the stock, down previously from $94.00.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Citigroup Inc. from $113.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Mizuho from $120.00 to $130.00. They now have an "outperform" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at B. Riley from $130.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $155.00. They now have an "overweight" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Rothschild & Co Redburn from $115.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $115.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Cantor Fitzgerald from $155.00 to $170.00. They now have an "overweight" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Rothschild & Co Redburn from $140.00 to $150.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at B. Riley from $160.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Needham & Company LLC from $150.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Citigroup Inc. from $120.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Mizuho from $162.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) was given a new $165.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) was given a new $200.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Lam Research (NASDAQ:LRCX) had its price target raised by analysts at Berenberg Bank from $122.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for LRCX provided by MarketBeat
Neueste Beiträge
SVB_Leerink_LLC in Ultragenyx Pharmaceutical Inc. diskutieren